alendronate

AssetSmall moleculeAlso MK0217, MK0217A, FOSAVANCE 5600, Maxmarvil

Inhibits farnesyl pyrophosphate synthase in osteoclasts to suppress bone resorption.

Stage: Approved
Modality: Small molecule
Target: Lipid and ceramide metabolism
Indications: 6
Trials: 75
Developers: 3

Indications

6

Glucocorticoid-induced osteoporosis
Approvedaccessdata.fda.gov7 Oct 2026
Osteoporosis
Approvedaccessdata.fda.gov7 Oct 2026
Paget disease of bone
Approvedaccessdata.fda.gov7 Oct 2026

3 more

Targets and what it contains2
Owner and partners3
Trials75
Evidence for its targets2
Competitors5
Signals2

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026 · 15 sources